Potentially improved response of COVID-19 vaccinated nasopharyngeal cancer patients to combination therapy with anti-PD-1 blockade and chemotherapy.
作者信息
Hua Y J, Liu Y L, Wen K, Kurts C, Wu H, Mei Q, Li J
机构信息
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou, China.
Institute of Molecular Medicine and Experimental Immunology, University Clinic of Rheinische Friedrich-Wilhelms-University, Bonn, Germany.
出版信息
Ann Oncol. 2023 Jan;34(1):121-123. doi: 10.1016/j.annonc.2022.10.002. Epub 2022 Oct 7.
Abstract
摘要
相似文献
1
Potentially improved response of COVID-19 vaccinated nasopharyngeal cancer patients to combination therapy with anti-PD-1 blockade and chemotherapy.接种新冠疫苗的鼻咽癌患者对抗PD-1阻断联合化疗的反应可能得到改善。
Ann Oncol. 2023 Jan;34(1):121-123. doi: 10.1016/j.annonc.2022.10.002. Epub 2022 Oct 7.
2
[Icotinib combined with radiotherapy for childhood nasopharyngeal carcinoma: A case report and review of the literature].[埃克替尼联合放疗治疗儿童鼻咽癌：1例病例报告及文献复习]
Zhonghua Zhong Liu Za Zhi. 2020 Oct 23;42(10):867-868. doi: 10.3760/cma.j.cn112152-20200325-00261.
3
Comparative safety and efficacy of anti-PD-1 monotherapy, chemotherapy alone, and their combination therapy in advanced nasopharyngeal carcinoma: findings from recent advances in landmark trials.抗 PD-1 单药治疗、单纯化疗及其联合治疗在晚期鼻咽癌中的比较安全性和疗效：来自标志性试验最新进展的研究结果。
J Immunother Cancer. 2019 Jun 25;7(1):159. doi: 10.1186/s40425-019-0636-7.
4
A Phase I/II Open-Label Study of Nivolumab in Previously Treated Advanced or Recurrent Nasopharyngeal Carcinoma and Other Solid Tumors.纳武利尤单抗治疗既往治疗的晚期或复发性鼻咽癌及其他实体瘤的 I/II 期开放标签研究。
Oncologist. 2019 Jul;24(7):891-e431. doi: 10.1634/theoncologist.2019-0284. Epub 2019 May 2.
5
A Phase II Study of Nivolumab plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17-11).一项评估纳武利尤单抗联合吉西他滨治疗复发性或转移性鼻咽癌患者的 II 期研究（KCSG HN17-11）。
Clin Cancer Res. 2022 Oct 3;28(19):4240-4247. doi: 10.1158/1078-0432.CCR-22-1238.
6
Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.节拍式卡培他滨作为局部晚期鼻咽癌辅助治疗：一项多中心、开放标签、平行分组、随机、对照、3 期临床试验。
Lancet. 2021 Jul 24;398(10297):303-313. doi: 10.1016/S0140-6736(21)01123-5. Epub 2021 Jun 7.
7
Induction chemotherapy is the best timekeeper in nasopharyngeal carcinoma.诱导化疗是鼻咽癌治疗中的最佳时间节点。
Cancer. 2020 Aug 15;126(16):3624-3626. doi: 10.1002/cncr.32971. Epub 2020 Jun 4.
8
Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials.卡瑞利珠单抗（SHR-1210）单药或联合吉西他滨加顺铂治疗鼻咽癌的疗效：两项单臂、1 期临床试验结果。
Lancet Oncol. 2018 Oct;19(10):1338-1350. doi: 10.1016/S1470-2045(18)30495-9. Epub 2018 Sep 10.
9
Revisiting induction chemotherapy before radiotherapy for head and neck cancer, part II: nasopharyngeal carcinoma.重新审视头颈部癌放疗前的诱导化疗，第二部分：鼻咽癌
Future Oncol. 2017 Mar;13(7):581-584. doi: 10.2217/fon-2016-0544.
10
Investigation of the Efficacy and Safety of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma.评估纳武利尤单抗在复发性和转移性鼻咽癌中的疗效和安全性。
In Vivo. 2020 Sep-Oct;34(5):2967-2972. doi: 10.21873/invivo.12127.
引用本文的文献
1
Periodic Boosters of COVID-19 Vaccines Do Not Affect the Safety and Efficacy of Immune Checkpoint Inhibitors for Advanced Non-Small Cell Lung Cancer: A Longitudinal Analysis of the Vax-On-Third Study.新冠疫苗的定期加强针不影响晚期非小细胞肺癌免疫检查点抑制剂的安全性和疗效：Vax-On-Third研究的纵向分析
Cancers (Basel). 2025 Jun 11;17(12):1948. doi: 10.3390/cancers17121948.
2
Improving CD3 bispecific antibody therapy in solid tumors using combination strategies.采用联合策略改善实体瘤中的CD3双特异性抗体治疗。
Front Oncol. 2025 Feb 10;15:1548446. doi: 10.3389/fonc.2025.1548446. eCollection 2025.
3
De novo myasthenia gravis in a patient with malignant melanoma after concurrent SARS-CoV-2 vaccination and immune checkpoint inhibitor therapy: Case report and literature review.一名恶性黑色素瘤患者在同时接种SARS-CoV-2疫苗和接受免疫检查点抑制剂治疗后发生的新发重症肌无力：病例报告及文献综述
eNeurologicalSci. 2024 Nov 13;37:100534. doi: 10.1016/j.ensci.2024.100534. eCollection 2024 Dec.
4
Exploring the protective association between COVID-19 infection and laryngeal cancer: insights from a Mendelian randomization study.探讨 COVID-19 感染与喉癌之间的保护关联：孟德尔随机化研究的启示。
Front Immunol. 2024 Jun 10;15:1380982. doi: 10.3389/fimmu.2024.1380982. eCollection 2024.
5
Nasopharynx Battlefield: Cellular Immune Responses Mediated by Midkine in Nasopharyngeal Carcinoma and COVID-19.鼻咽战场：中期因子在鼻咽癌和新冠肺炎中介导的细胞免疫反应
Cancers (Basel). 2023 Oct 4;15(19):4850. doi: 10.3390/cancers15194850.
6
COVID-19 vaccination is associated with enhanced efficacy of anti-PD-(L)1 immunotherapy in advanced NSCLC patients: a real-world study.新冠病毒疫苗接种与晚期非小细胞肺癌患者抗程序性死亡受体-（配体）1免疫治疗疗效增强相关：一项真实世界研究
Infect Agent Cancer. 2023 Sep 7;18(1):50. doi: 10.1186/s13027-023-00526-7.
7
The Effect of mRNA-Based COVID-19 Vaccination on Anti-Programmed Cell Death Protein 1 Blockade for Nasopharyngeal Cancer May Differ From a Virus-Inactivated Vaccine.基于信使核糖核酸的新冠疫苗接种对鼻咽癌程序性细胞死亡蛋白1阻断治疗的影响可能与灭活病毒疫苗不同。
World J Oncol. 2023 Aug;14(4):316-320. doi: 10.14740/wjon1620. Epub 2023 Jul 12.
8
Persistence of Immune Response Elicited by Three Doses of mRNA Vaccine against SARS-CoV-2 in a Cohort of Patients with Solid Tumors: A One-Year Follow-Up.mRNA 疫苗接种三剂后对实体瘤患者引发的免疫应答持久性：一年随访。
Int J Mol Sci. 2023 Apr 4;24(7):6731. doi: 10.3390/ijms24076731.
9
Add fuel to the fire: Inflammation and immune response in lung cancer combined with COVID-19.火上浇油：肺癌合并 COVID-19 中的炎症和免疫反应。
Front Immunol. 2023 Mar 23;14:1174184. doi: 10.3389/fimmu.2023.1174184. eCollection 2023.
Zotero 插件